Clinical Trial Update: Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating palbociclib and trastuzumab with endocrine therapy in HER2-positive metastatic breast cancer has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Palbociclib (palbociclib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: SOLTI Breast Cancer Research Group | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED